These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33526860)

  • 1. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
    Estupiñán HY; Wang Q; Berglöf A; Schaafsma GCP; Shi Y; Zhou L; Mohammad DK; Yu L; Vihinen M; Zain R; Smith CIE
    Leukemia; 2021 May; 35(5):1317-1329. PubMed ID: 33526860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.
    Hamasy A; Wang Q; Blomberg KE; Mohammad DK; Yu L; Vihinen M; Berglöf A; Smith CI
    Leukemia; 2017 Jan; 31(1):177-185. PubMed ID: 27282255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
    Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
    Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
    Woyach JA
    Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
    [No Abstract]   [Full Text] [Related]  

  • 6. Bruton's tyrosine kinase (BTK) inhibitors alter blood glucose and insulin in obese mice but reduce inflammation independent of BTK.
    Chan DY; Barra NG; Fang H; Rodrigues E-Lacerda R; Schertzer JD
    Am J Physiol Endocrinol Metab; 2024 Sep; 327(3):E271-E278. PubMed ID: 39017678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
    Johnson AR; Kohli PB; Katewa A; Gogol E; Belmont LD; Choy R; Penuel E; Burton L; Eigenbrot C; Yu C; Ortwine DF; Bowman K; Franke Y; Tam C; Estevez A; Mortara K; Wu J; Li H; Lin M; Bergeron P; Crawford JJ; Young WB
    ACS Chem Biol; 2016 Oct; 11(10):2897-2907. PubMed ID: 27571029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
    Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
    Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
    J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Means and Challenges in the Targeting of BTK.
    Nawaratne V; Sondhi AK; Abdel-Wahab O; Taylor J
    Clin Cancer Res; 2024 Jun; 30(11):2333-2341. PubMed ID: 38578606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
    Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
    Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
    O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
    Front Immunol; 2019; 10():2129. PubMed ID: 31552054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
    Dostálová H; Kryštof V
    Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
    Cheng S; Guo A; Lu P; Ma J; Coleman M; Wang YL
    Leukemia; 2015 Apr; 29(4):895-900. PubMed ID: 25189416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Jain P; Kanagal-Shamanna R; San Lucas FA; Nastoupil L; Romaguera J; Fayad L; Oki Y; Westin JR; Medeiros LJ; Wang M; Fowler N
    Br J Haematol; 2018 Sep; 182(5):718-723. PubMed ID: 28771675
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
    Tam CS; Ou YC; Trotman J; Opat S
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
    [No Abstract]   [Full Text] [Related]  

  • 20. Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.
    Elamin G; Aljoundi A; Alahmdi MI; Abo-Dya NE; Soliman MES
    J Mol Model; 2022 Oct; 28(11):355. PubMed ID: 36222928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.